MVP方案新辅助化疗治疗ⅢA期非小细胞肺癌的疗效观察  

Clinical Efficacy of Neo-adjuvant Chemotherapy with MVP Method for Stage ⅢA Non-small Cell Lung Cancer

作　　者：石鹏飞 张晓明 

机构地区：[1]陕西省咸阳市第一人民医院,712000

出　　处：《实用癌症杂志》2016年第5期769-771,共3页The Practical Journal of Cancer

摘　　要：目的观察MVP方案新辅助化疗治疗ⅢA期非小细胞肺癌的疗效。方法选择80例ⅢA期非小细胞肺癌患者作为研究对象,将术前采用MVP方案进行新辅助化疗的患者设为观察组,直接进行手术治疗的患者设为对照组,2组各40例。对2组近期疗效、并发症发生率及1、3、5年生存率进行对比。结果观察组总有效率为77.5%,对照组总有效率为55.0%,差异有统计学意义(P<0.05)。2组患者并发症发生情况无统计学差异(P>0.05)。在生存率方面,2组患者1年生存率无统计学差异(P>0.05),但观察组3年生存率及5年生存率明显高于对照组(P<0.05)。结论MVP方案新辅助化疗可提高临床疗效而不增加术后并发症,且能延长患者生存期,值得临床推广应用。Objective To observe the clinical efficacy of the neo-adjuvant chemotherapy with MVP method for stage ⅢA non-small lung cancer. Methods Clinical data of 80 patients with ⅢA stage non-small lung cancer were analyzed retrospectively. The patients underwent neo-adjuvant chemotherapy with MVP method were collected as the observation group,and the patients underwent surgery without chemotherapy were collected as the control group,each group had 40 cases. Then the efficacy,complications and 1-,3- and 5-year survival rate of the 2 groups were compared. Results The total efficacy of the observation group was 77. 5%,which was obviously higher than that of the control group,55. 0%（ P〈0. 05）. There were no statistically different between the 2 groups in the incidence of complication（ P〉0. 05）. 1-year survival rate of the 2 groups had no statistical difference（ P〉0. 05）,but 3- and 5-year survival rate of the observation group were higher than those of the control group（ P〈0. 05）. Conclusion Neo-adjuvant chemotherapy with MVP method for stage Ⅲ A non-small cell lung cancer can improve the clinical efficacy and survival with less complications,it is worthy of clinical application.

关 键 词：新辅助化疗 ⅢA期非小细胞肺癌 疗效观察 

分 类 号：R734.2[医药卫生—肿瘤]